News
IDIBELL researchers identify a brain region that predicts the evolution of apathy in Huntington’s patients
The atrophy of a specific region of the cerebral cortex is related to the appearance of apathy in Huntington’s patients, a neurodegenerative disease that affects motor and cognitive function. This is the conclusion of a study of the Bellvitge Biomedical Research Institute (IDIBELL) published in the Movement Disorders journal.
May 12 – International Nursing Day
The date of the election to celebrate this anniversary coincides with the birth of nurse Florence Nightingale, a pioneer of modern nursing
Researchers identify a possible therapy against Rendu-Osler disease
Research It is a rare disease that causes malformations in blood vessels. The study has discovered the implication of a protein in the development of the pathology.
Isabel Fabregat receives a grant from the Ramón Areces Foundation to study liver fibrosis
The Ramón Areces Foundation has awarded Grants for Research in Life Sciences and Matter corresponding to its 20th edition. In intercellular dialogue and interactome area, Dr. Isabel Fabregat, head of the research group “TGF-beta and cancer” at IDIBELL, in collaboration with Drs. Aránzazu Sánchez and Blanca Herrera from the Complutense University of Madrid, have received one of the grants.
60% of Covid-19 patients develop neurological symptoms
60% of Covid-19 inpatients develop neurological symptoms and 12% of post-Covid patients have neurological sequelae.
Saturday was the day to enjoy and experiment in the Hospitalet science park
This year within the framework of the Hospitalet Spring Festival, we enjoyed again in the Science Park.
We launch VacunAcció: a project to immunize against fake news
IDIBELL and the Virolai school, together in a new educational initiative of the Escolab program of the Barcelona City Council
IDIBELL and Bellvitge Hospital lead a study on the effectiveness of icatibant against COVID-19
Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.